Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Pfizer (NYSE: PFE) announced positive results from its Phase 3 TALAPRO-2 study of TALZENNA (talazoparib) combined with XTANDI (enzalutamide) for men with metastatic castration-resistant prostate cancer (mCRPC), achieving the primary endpoint of radiographic progression-free survival (rPFS) with a hazard ratio of 0.696. Consistent efficacy was noted irrespective of homologous recombination repair gene mutations. While a trend towards improved overall survival was observed, it needs further analysis. Safety profiles were generally consistent with known data, paving the way for potential regulatory discussions.
Pfizer has completed its acquisition of Biohaven Pharmaceutical for $11.6 billion, paying $148.50 per share. This acquisition adds the innovative migraine therapy NURTEC® ODT and a portfolio of CGRP receptor antagonists, including rimegepant and zavegepant, to Pfizer's pipeline. These drugs aim to serve over 1 billion migraine patients globally. The merger enhances Pfizer's Internal Medicine portfolio with strong growth potential through 2030 and beyond. Biohaven became a wholly-owned subsidiary, while Biohaven Ltd. retained non-CGRP assets and will continue trading under the ticker BHVN.
Pfizer (PFE) and BioNTech (BNTX) announced the submission of a request to the FDA for Emergency Use Authorization of a 10-µg booster dose of their bivalent COVID-19 vaccine targeting the Omicron BA.4/BA.5 variant for children aged 5-11. This request is backed by safety and immunogenicity data. Additionally, a Phase 1/2/3 study has been initiated to evaluate the vaccine's safety and immune response among children aged 6 months to 11 years. The companies also plan to submit a marketing authorization application to the EMA for the same age group.
Pfizer Inc. (NYSE: PFE) has declared a $0.40 cash dividend for Q4 2022, marking the 336th consecutive quarterly dividend payment. The dividend will be payable on December 5, 2022, to shareholders on record as of November 4, 2022. This announcement highlights the company's ongoing commitment to return value to its shareholders.
Pfizer (NYSE: PFE) has announced an agreement to supply up to six million treatment courses of its COVID-19 oral treatment, PAXLOVID™, to the Global Fund for low-and-middle-income countries. These treatment courses will be available for procurement in 132 eligible countries beginning in 2022, pending regulatory approval. The agreement is part of Pfizer's strategy for equitable access to COVID-19 treatments. Additionally, Pfizer has established tiered pricing for different income classifications and signed prior agreements with UNICEF and the Medicines Patent Pool to enhance global access.
Pfizer Inc. (NYSE: PFE) is hosting a conference call for investors on November 1, 2022, at 10 a.m. EDT to discuss its Third Quarter 2022 Performance Report. The call will provide insights into the company's financial results and future strategies. Interested participants can join via webcast or by dialing specific numbers for different regions. Details for accessing the Performance Report and registration can be found on Pfizer's investor website, with a transcript available within 24 hours post-call.
Pfizer announced positive results from its pivotal Phase 3 study (NCT04546425) for its 20-valent pneumococcal conjugate vaccine candidate (20vPnC), targeting invasive pneumococcal disease in infants. The vaccine showed a favorable safety profile and robust immune responses, meeting non-inferiority criteria for 19 of 20 serotypes after the third dose. Pfizer intends to file for regulatory approval in the EU in the upcoming months. This vaccine, if approved, would provide comprehensive protection against pneumococcal disease, marking a significant milestone in pediatric vaccination.
Pfizer announced positive results from the Phase 3 trial of its investigational pentavalent meningococcal vaccine, MenABCWY, demonstrating safety and immunogenicity non-inferior to existing licensed vaccines. The trial met all primary and secondary endpoints, providing broad serogroup coverage. Pfizer plans to submit a Biologics License Application to the FDA in Q4 2022, which, if approved, could simplify the vaccination schedule for approximately 52 million adolescents in the U.S. and improve meningococcal disease protection.
Pfizer Inc. (NYSE: PFE) will hold a conference call on September 21, 2022, at 4:30 p.m. EDT, focusing on oral GLP-1 data from the European Association for the Study of Diabetes 2022. Investors can join the webcast via Pfizer's investor site, and are encouraged to register in advance. Participants can also listen by calling 800-456-4352 (U.S. and Canada) or 785-424-1086 (international), with passcode “70409”. A transcript and replay will be available for 90 days on the investor site.
Pfizer Inc. (NYSE: PFE) has initiated a pivotal Phase 3 clinical trial for its mRNA-based influenza vaccine, enrolling approximately 25,000 healthy adults in the U.S. This study aims to evaluate the vaccine's efficacy, safety, and immunogenicity. With influenza annually causing up to 710,000 hospitalizations and 52,000 deaths in the U.S., the need for improved vaccines is critical. mRNA technology may allow better strain matches and more rapid production, potentially enhancing vaccine effectiveness.